CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Senate Resolution No. 67Introduced by Senator ArchuletaFebruary 10, 2022 Relative to Tardive Dyskinesia Awareness Week.LEGISLATIVE COUNSEL'S DIGESTSR 67, as introduced, Archuleta. Digest KeyBill TextWHEREAS, Many people with serious, chronic mental illness, such as schizophrenia and other schizoaffective disorders, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics; andWHEREAS, While ongoing treatment with these medications can be very helpful, and even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD); andWHEREAS, Many people who have gastrointestinal disorders, including gastroparesis, nausea, and vomiting, also require treatment with DRBAs; andWHEREAS, Treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to TD; andWHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities. In some cases, people may experience movement of the arms, legs, fingers, and toes. In some case, it may affect the tongue, lips, and jaw. In other cases, symptoms may include swaying movements of the trunk or hips and may impact the muscles associated with walking, speech, eating, and breathing; andWHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after they have discontinued use of those medications. Not everyone who takes a DRBA develops TD, but if it develops, it is often permanent; andWHEREAS, Common risk factors for TD include advanced age and alcoholism or other substance abuse disorders. Postmenopausal women and people with a mood disorder are also at higher risk of developing TD; andWHEREAS, A person is at higher risk for TD after taking DRBAs for three months or longer, but the longer the person is on these medications, the higher the risk of developing TD; andWHEREAS, Studies suggest that overall risk of developing TD is between 10 and 30 percent; andWHEREAS, It is estimated that over 500,000 Americans suffer from TD. According to the National Alliance for Mental Illness, one in every four patients receiving long-term treatment with an antipsychotic medication will experience TD; andWHEREAS, Years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for TD approved by the United States Food and Drug Administration; andWHEREAS, TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA medications is recommended by the American Psychiatric Association; andWHEREAS, Patients suffering from TD often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; andWHEREAS, Caregivers of patients with TD face many challenges and are often responsible for the overall care of the TD patient; andWHEREAS, The Senate can raise awareness of TD in the public and medical community; now, therefore, be itResolved by the Senate of the State of California, That the Senate proclaims the week of May 1, 2022, as Tardive Dyskinesia Awareness Week, and encourages everyone in the United States to become better informed about, and aware of, Tardive Dyskinesia; and be it furtherResolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Senate Resolution No. 67Introduced by Senator ArchuletaFebruary 10, 2022 Relative to Tardive Dyskinesia Awareness Week.LEGISLATIVE COUNSEL'S DIGESTSR 67, as introduced, Archuleta. Digest Key
CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION
Senate Resolution
No. 67
Introduced by Senator ArchuletaFebruary 10, 2022
Introduced by Senator Archuleta
February 10, 2022
Relative to Tardive Dyskinesia Awareness Week.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
SR 67, as introduced, Archuleta.
## Digest Key
## Bill Text
WHEREAS, Many people with serious, chronic mental illness, such as schizophrenia and other schizoaffective disorders, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics; and
WHEREAS, While ongoing treatment with these medications can be very helpful, and even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD); and
WHEREAS, Many people who have gastrointestinal disorders, including gastroparesis, nausea, and vomiting, also require treatment with DRBAs; and
WHEREAS, Treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to TD; and
WHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities. In some cases, people may experience movement of the arms, legs, fingers, and toes. In some case, it may affect the tongue, lips, and jaw. In other cases, symptoms may include swaying movements of the trunk or hips and may impact the muscles associated with walking, speech, eating, and breathing; and
WHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after they have discontinued use of those medications. Not everyone who takes a DRBA develops TD, but if it develops, it is often permanent; and
WHEREAS, Common risk factors for TD include advanced age and alcoholism or other substance abuse disorders. Postmenopausal women and people with a mood disorder are also at higher risk of developing TD; and
WHEREAS, A person is at higher risk for TD after taking DRBAs for three months or longer, but the longer the person is on these medications, the higher the risk of developing TD; and
WHEREAS, Studies suggest that overall risk of developing TD is between 10 and 30 percent; and
WHEREAS, It is estimated that over 500,000 Americans suffer from TD. According to the National Alliance for Mental Illness, one in every four patients receiving long-term treatment with an antipsychotic medication will experience TD; and
WHEREAS, Years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for TD approved by the United States Food and Drug Administration; and
WHEREAS, TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA medications is recommended by the American Psychiatric Association; and
WHEREAS, Patients suffering from TD often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; and
WHEREAS, Caregivers of patients with TD face many challenges and are often responsible for the overall care of the TD patient; and
WHEREAS, The Senate can raise awareness of TD in the public and medical community; now, therefore, be it
Resolved by the Senate of the State of California, That the Senate proclaims the week of May 1, 2022, as Tardive Dyskinesia Awareness Week, and encourages everyone in the United States to become better informed about, and aware of, Tardive Dyskinesia; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.